rthepple.bsky.social
Scientist, lifelong athlete, home cook, music lover and amateur musician, husband, father, brother, son. Research interests: aging, cancer cachexia, sepsis, skeletal muscle and mitochondria. Did I mention mitochondria?
26 posts
338 followers
166 following
Regular Contributor
Active Commenter
comment in response to
post
We should also have one for Canadian scientists in US. Stronger together regardless of borders. You know, the way it was before all this 51st state rhetoric. For the record, I love my American colleagues (that’s why I moved here) and think the current situation is an insult to us all.
comment in response to
post
Absolutely beautiful work.
comment in response to
post
Thanks to @droch.bsky.social for correction - this should be Novo Nordisk not Roche
comment in response to
post
Thanks Julien. I questioned this after I hit send and was going to try to edit.
comment in response to
post
But I think your statement only applies if academia generates a compound because a process or pathway cannot be patented and any returns on compound go to university not NIH. I was thinking of what happens with Roche in Denmark but I am not versed in roadblocks here in US
comment in response to
post
Begging the question of why it is not mandated that a return of a percentage of profits on said drugs go back to fund NIH research.
comment in response to
post
Congratulations Kevin!
comment in response to
post
I wonder how specific this may be to ALS? Aging also causes Tdp43 dysfunction (risk of ALS increases w age) www.nature.com/articles/s42... so perhaps this is more about importance of CoxIV to motoneuron survival than ALS per se?
comment in response to
post
Please congratulate Casper and rest of your team for me!
comment in response to
post
... gait speed. Still better than anything molecular biomarkers can provide. Our commentary (with @regula-furrer.bsky.social @biozentrum.unibas.ch @unibas.ch) out now in NPJ Aging:
doi.org/10.1038/s415...
3/3
comment in response to
post
Just drop me a line, Vincent! Gilles knows how to reach me.
comment in response to
post
We should try to partner with MoTrPAc to get comparator data on younger participants. Just a thought.
comment in response to
post
Sounds like a plan! I think an important component will be to address heterogeneity. My sense is that some will be responsive and others not so much.
comment in response to
post
It is this period when preservation of oxphos might become the cause of greater voluntary exercise rather than the result. Let’s call it a hypothesis 😊
comment in response to
post
Thanks for the very thoughtful reply, Gilles! I have no issue about exercise increasing oxphos except to make the point that I am not aware of any data addressing those >75 y, a time when the anabolic response to strength training is lost. pubmed.ncbi.nlm.nih.gov/18448613/
comment in response to
post
Great work Gilles and team! To what degree do you think those who remain active with aging do so because they maintain mitochondrial oxphos capacity, rather than maintained oxphos being the outcome of being active?
comment in response to
post
Since it seems that mito fusion can occur during an acute bout of exercise pubmed.ncbi.nlm.nih.gov/31398297/, I wonder if that response becomes impaired with aging and explains the more fragmented mito morphology in older humans?
comment in response to
post
Please add me!
comment in response to
post
Sounds like interesting stuff. I will see you there!
comment in response to
post
Count me in. We use mouse models of aging, cancer cachexia and sepsis.
comment in response to
post
I made a crawfish gumbo, chicken jambalaya and a pork verde stew for my lab group party yesterday. No pics of the food but I have a stack of pots that I cleaned today that I could submit!